Hydroxy-PEG5-Boc
CAS No. 850090-09-4
Hydroxy-PEG5-Boc( —— )
Catalog No. M24846 CAS No. 850090-09-4
Hydroxy-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 26 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHydroxy-PEG5-Boc
-
NoteResearch use only, not for human use.
-
Brief DescriptionHydroxy-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
DescriptionHydroxy-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
In VitroPROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPEGs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number850090-09-4
-
Formula Weight366.45
-
Molecular FormulaC17H34O8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(OC(C)(C)C)CCOCCOCCOCCOCCOCCO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
molnova catalog
related products
-
QCA570
QCA570 is a novel, highly potent efficacious BET degrader (PROTAC); effectively induces degradation of BET proteins and inhibits cell growth in human acute leukemia cell lines at pM level.
-
dBET57
dBET57 is a novel BRD4 heterobifunctional small-molecule ligand (PROTAC), exhibits significant and selective degradation of BRD4 BD1 (DC50/5h=500 nM).
-
PAC
PAC1 (Compound PAC1) is a novel PROTAC antibody conjugate, more potent estrogen receptor-alpha (ERα) degrader compared to PROTAC without antibody conjugation.
Cart
sales@molnova.com